Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inflammatory biomarkers and hyperreflective foci changes in diabetic macular edema treated with aflibercept
KCT0003712Phase 4Completed
- Sponsor
- Bayer
- Start
- May 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in diabetic macular edema (DME), sponsored by Bayer. Started May 2019; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on KCT0003712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003712.